Zentalis Pharmaceuticals Shares Updated Clinical Data Demonstrating Meaningful Azenosertib Activity in Cyclin E1+, Platinum-Resistant Ovarian Cancer
Results from DENALI Part 1b show an Objective Response Rate (ORR) of…
Results from DENALI Part 1b show an Objective Response Rate (ORR) of…
Sign in to your account